비알코올성 지방간염 치료 시장 규모, 점유율, 성장 분석 : 약물 종류별, 병기별, 유통 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Non-Alcoholic Steatohepatitis Treatment Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 4.24 Billion in 2025 to USD 18.85 Billion by 2033, growing at a CAGR of 20.32% during the forecast period (2026-2033).

The market for non-alcoholic steatohepatitis (NASH) treatment is being fueled by the increasing rates of obesity and type 2 diabetes, alongside a rise in liver diseases and heightened awareness of NASH. Innovations in targeted therapeutics and substantial investments in liver disease research are further bolstering demand. The surge in clinical studies and heightened spending on drug development underscore the recognition of NASH as a distinct medical field. Despite challenges such as high treatment costs, early diagnosis difficulties, and regulatory complexities, the push for innovative drug candidates and combination therapies is gaining traction. Advancements in imaging techniques and non-invasive diagnostic tests are improving patient monitoring, while emerging evidence for metabolic drugs is expanding treatment options and encouraging acceptance in the healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Alcoholic Steatohepatitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Alcoholic Steatohepatitis Treatment Market Segments Analysis

Global non-alcoholic steatohepatitis treatment market is segmented by drug class, stage, distribution channel, end-user, and region. Based on drug class, the market is segmented into FXR Agonists, THR-B Agonists (Resmetirom), SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Pan-PPAR Agonists. Based on stage, the market is segmented into NASH without Cirrhosis and NASH with Cirrhosis. Based on distribution channel, the market is segmented into hospital pharmacies and specialty pharmacies. Based on end-user, the market is segmented into hepatology clinics, hospitals, and gastroenterology practices. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Non-Alcoholic Steatohepatitis Treatment Market

The development of noninvasive imaging techniques, biomarkers, and advanced diagnostics significantly enhances the accuracy of diagnosing and staging nonalcoholic steatohepatitis, facilitating the screening and treatment of a larger patient population, as well as their inclusion in clinical trials. This improved clarity in diagnosis promotes personalized treatment strategies, allowing healthcare providers to better identify candidates for emerging therapies, fostering greater acceptance among both patients and physicians. Additionally, the heightened diagnostic precision leads to improved therapeutic outcomes, encouraging further investment in treatments and increasing adoption rates across healthcare facilities, ultimately driving robust growth in the global market.

Restraints in the Global Non-Alcoholic Steatohepatitis Treatment Market

The global non-alcoholic steatohepatitis treatment market faces significant challenges due to the variations in regulatory approval processes across different regions. These discrepancies introduce an element of unpredictability for developers seeking approval for their therapies, ultimately slowing down the timeline from clinical trials to market readiness. Each jurisdiction has differing requirements for evidence, endpoint definitions, and extensive post-marketing surveillance, which complicates the development process. This complexity not only amplifies risks for sponsors but also complicates commercial launch and market access strategies. Consequently, it may deter investment and delay product introductions, adversely affecting market growth and patient accessibility.

Market Trends of the Global Non-Alcoholic Steatohepatitis Treatment Market

The Global Non-Alcoholic Steatohepatitis (NASH) Treatment market is witnessing a significant shift towards precision medicine, emphasizing personalized approaches that involve biomarker-driven diagnostics. Stakeholders are increasingly prioritizing the development of tailored treatment regimens that enhance clinical outcomes and minimize patient variability. Collaborations between drug developers and diagnostic firms are emerging to capitalize on these advancements, paving the way for innovative combination therapies and adaptive clinical trial designs. Furthermore, payers are shifting their focus toward patient-level value, creating reimbursement pathways that reward effective and predictably safe treatments in targeted populations, ultimately shaping a more specialized and effective landscape in NASH therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Non-Alcoholic Steatohepatitis Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• FXR Agonists
• THR-B Agonists (Resmetirom)
• SGLT2 Inhibitors
• GLP-1 Receptor Agonists
• Pan-PPAR Agonists

Global Non-Alcoholic Steatohepatitis Treatment Market Size by Stage & CAGR (2026-2033)

• Market Overview
• NASH without Cirrhosis
• NASH with Cirrhosis

Global Non-Alcoholic Steatohepatitis Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Non-Alcoholic Steatohepatitis Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hepatology Clinics
• Hospitals
• Gastroenterology Practices

Global Non-Alcoholic Steatohepatitis Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Stage, Distribution, End-User)
  • US
  • Canada
• Europe (Drug Class, Stage, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Stage, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Stage, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Stage, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Madrigal Pharmaceuticals (Rezdiffra)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Semaglutide)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Tirzepatide)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intercept Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genfit SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akero Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 89bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CymaBay Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inventiva SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metacrine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axcella Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cirius Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HighTide Biopharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pliant Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (AbbVie)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations